Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Apr:33:49-53.
doi: 10.1016/j.yebeh.2014.02.011. Epub 2014 Mar 13.

Carbamazepine clearance and seizure stability during pregnancy

Emily L Johnson  1 , Zachary N Stowe  2 , James C Ritchie  3 , D Jeffrey Newport  4 , Melanee L Newman  5 , Bettina Knight  2 , Page B Pennell  6
Affiliations
Observational Study

Carbamazepine clearance and seizure stability during pregnancy

Emily L Johnson et al. Epilepsy Behav. 2014 Apr.

Abstract

The aims of this study were to characterize the alterations in total and free carbamazepine (CBZ) and in total and free carbamazepine-epoxide (CBZ-EPO) clearances during pregnancy, to calculate the change in free fractions of CBZ and CBZ-EPO during pregnancy, and to determine whether seizure worsening is associated with a low ratio to nonpregnant baseline concentration of total or free CBZ or CBZ-EPO. Women on CBZ were enrolled before conception or during pregnancy in this prospective, observational study. Concomitant medications and seizure frequency were recorded. Serum total and free CBZ and CBZ-EPO were collected at each visit. Changes in the clearance of all four compounds and free fractions of CBZ and CBZ-EPO were compared with nonpregnant baseline. During pregnancy, the ratios to baseline concentrations of total and free CBZ and CBZ-EPO were compared for months with and without increased seizure frequency. Total and free CBZ and CBZ-EPO clearances were calculated in 15 pregnancies in 12 women. Clearances did not change for any of these compounds during pregnancy. The free fraction of CBZ increased from 0.23 at baseline to a maximum of 0.32 in the third trimester (p=0.008). In the six women on CBZ monotherapy with adequate seizure diaries and blood sampling, seizure worsening did not correspond to a ratio to baseline concentration of less than 0.65 for total or free CBZ or CBZ-EPO. In conclusion, total and free CBZ and CBZ-EPO clearances did not change substantially during pregnancy, and seizure frequency worsening was not associated with decreased concentrations of total or free CBZ; therefore, therapeutic drug monitoring may not be necessary for all women on CBZ during pregnancy. Further studies with larger sample sizes are needed before definitive recommendations can be made. Carbamazepine monotherapy may be a relatively safe and cost effective treatment option for women with focal epilepsy syndromes during pregnancy.

Keywords: Carbamazepine; Clearance; Epilepsy; Free carbamazepine; Pregnancy; Seizure.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of women enrolled in the study and information used for data analysis
Figure 2
Figure 2
Clearance of compounds throughout pregnancy (95% confidence intervals shown with error bars)
Figure 3
Figure 3
Free Fraction of CBZ and CBZ-EPO (95% confidence intervals shown with error bars)
See this image and copyright information in PMC

References

    1. Harden CL, Pennell PB, Koppel BS, et al. Practice Parameter Update: Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding. Neurology. 2009;73:142–149. - PMC - PubMed
    1. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in Pregnancy: Clearance, Therapeutic Drug Monitoring, and Seizure Frequency. Neurology. 2008;70:2130–2136. - PMC - PubMed
    1. International League Against Epilepsy. [Accessed 2/1/13];Worldwide AED Database. Available at: http://www.ilae.org/Visitors/Centre/AEDs/index.cfm.
    1. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692–9. - PubMed
    1. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10:609–17. - PubMed

Publication types